Hemostemix Inc.
HMTXF
$0.0703
$0.00385.71%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 200.60K | 264.00K | 238.90K | 421.00K | 281.50K |
Depreciation & Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 200.60K | 264.00K | 241.10K | 340.30K | 283.30K |
Operating Income | -200.60K | -264.00K | -241.10K | -340.30K | -283.30K |
Income Before Tax | -230.60K | -379.50K | -352.70K | -502.50K | -191.80K |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -230.60K | -379.50K | -352.70K | -502.50K | -191.80K |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -230.60K | -379.50K | -352.70K | -502.50K | -191.80K |
EBIT | -200.60K | -264.00K | -241.10K | -340.30K | -283.30K |
EBITDA | -200.60K | -264.00K | -241.10K | -340.20K | -283.30K |
EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
Average Basic Shares Outstanding | 87.12M | 87.12M | 87.12M | 98.73M | 84.51M |
Average Diluted Shares Outstanding | 87.12M | 87.12M | 87.12M | 98.73M | 84.51M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |